MET and cholangiocarcinoma: Other targets, such as anti-angiogenesis, EGFR amp, WNT/a-catenin, Hedgehog, and HGF/c-MET, have been reported in cholangiocarcinoma, but most of these pathways can be found in most tumour types, and multiple previous clinical trials in cholangiocarcinoma have shown limited effectiveness.